Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating parsaclisib with rituximab or obinutuzumab in relapsed/refractory follicular lymphoma and marginal zone lymphoma has been wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• Parsaclisib (parsaclisib)
• Rituximab (rituximab)

Snippet

Sponsor: Incyte Corporation | Conditions: Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | Phase 3 | Status: WITHDRAWN